Cystitis secondary prevention: Difference between revisions

Jump to navigation Jump to search
(Category)
No edit summary
Line 28: Line 28:
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WH}}
{{WS}}[[Category:Emergency medicine]]
{{WS}}
[[Category:Disease]]
[[Category:Medicine]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Nephrology]]
[[Category:Nephrology]]
[[Category:Urology]]
[[Category:Urology]]
[[Category:Up-To-Date]]
[[Category:Primary care]]

Revision as of 13:45, 19 June 2018

Urinary Tract Infections Main Page

Cystitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cystitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultarsound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Tests

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cystitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cystitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cystitis secondary prevention

CDC on Cystitis secondary prevention

Cystitis secondary prevention in the news

Blogs on Cystitis secondary prevention

Directions to Hospitals Treating Cystitis

Risk calculators and risk factors for Cystitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D., Usama Talib, BSc, MD [2]

Overview

Secondary prophylaxis of cystitis is useful to prevent recurrent cystitis. It is more beneficial in patients in which cystitis is associated with sexual intercourse, a structural defect or a disease like diabetes that can lead to recurrent infections.

Secondary Prevention

The secondary prevention of cystitis includes the prophylaxis to prevent recurrent cystitis.

Antimicrobial Prophylaxis

  • Prophylaxis is required in individuals having two or more episodes in 6 months or three or more episodes in 12 months period.[1][2]
  • Prophylactic therapy using antimicrobial agents may be considered as either continuously or postcoital prophylaxis for 6 to 12 months.
  • The following regimens may be used as single doses prior to sexual activity.[3]
  • Prophylactic Therapy:
  • Preferred regimen (1): Fosfomycin tromethamine 3 g PO in a single dose
  • Preferred regimen (2): Nitrofurantoin monohydrate/macrocrystals 100 mg PO in a single dose
  • Preferred regimen (3): Trimethoprim-Sulfamethoxazole 160/800 mg PO double-strength tablet bid in a single dose
  • Preferred regimen (4): Trimethoprim 100 mg PO bid in a single dose
  • Alternative regimen (1): Ciprofloxacin 250 mg PO bid in a single dose
  • Alternative regimen (2): Levofloxacin 250 mg PO qd in a single dose
  • Alternative regimen (3): Norfloxacin 400 mg PO bid in a single dose
  • Alternative regimen (4): Gatifloxacin 200 mg PO qd in a single dose

References

  1. Nicolle LE, Ronald AR (1987). "Recurrent urinary tract infection in adult women: diagnosis and treatment". Infect Dis Clin North Am. 1 (4): 793–806. PMID 3333659.
  2. Ronald AR, Conway B (1988). "An approach to urinary tract infections in ambulatory women". Curr Clin Top Infect Dis. 9: 76–125. PMID 3077293.
  3. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG; et al. (2011). "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases". Clin Infect Dis. 52 (5): e103–20. doi:10.1093/cid/ciq257. PMID 21292654.
  4. Melekos MD, Asbach HW, Gerharz E, Zarakovitis IE, Weingaertner K, Naber KG (1997). "Post-intercourse versus daily ciprofloxacin prophylaxis for recurrent urinary tract infections in premenopausal women". J Urol. 157 (3): 935–9. PMID 9072603.
  5. Brumfitt W, Hamilton-Miller JM (1998). "Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience". J Antimicrob Chemother. 42 (3): 363–71. PMID 9786476.
  6. Rudenko N, Dorofeyev A (2005). "Prevention of recurrent lower urinary tract infections by long-term administration of fosfomycin trometamol. Double blind, randomized, parallel group, placebo controlled study". Arzneimittelforschung. 55 (7): 420–7. doi:10.1055/s-0031-1296881. PMID 16080282.

Template:WH Template:WS